

Published by
Ministry of Health, Labour and Welfare



Translated by
Pharmaceuticals and Medical Devices Agency



This English version is intended to be a reference material to provide convenience for users. In the event of inconsistency between the Japanese original and this English translation, the former shall prevail.

Revision of Precautions

Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate)

May 29, 2023

Therapeutic category

Vaccines

Non-proprietary name

Haemophilus influenzae type b conjugate vaccine (tetanus toxoid conjugate)

Safety measure

Precautions should be revised.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
E-mail: safety.info@pmda.go.jp

Revision in line with the Instructions for Electronic Package Inserts of Prescription Drugs, etc. PSEHB Notification No. 0611-1 by the Director-General of Pharmaceutical Safety and Environmental Health Bureau, MHLW, dated June 11, 2021 (New instructions):

Revised language is underlined.

Current	Revision
<p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>Individuals who receive vaccinations and timing of vaccination</p> <p>This vaccine should be administered to individuals aged 2 months or over and under 5 years. Vaccination should be initiated at ages of 2 months or over and under 7 months as the standard practice.</p> <p>9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS</p> <p>9.1 Persons to be vaccinated with caution</p> <p>(N/A)</p>	<p>7. PRECAUTIONS CONCERNING DOSAGE AND ADMINISTRATION</p> <p>Individuals who receive vaccinations and timing of vaccination</p> <p><u>Usually</u>, this vaccine should be administered to individuals aged 2 months or over and under 5 years. Vaccination should be initiated at ages of 2 months or over and under 7 months as the standard practice.</p> <p>9. PRECAUTIONS CONCERNING PATIENTS WITH SPECIFIC BACKGROUNDS</p> <p>9.1 Persons to be vaccinated with caution</p> <p><u>Individuals with decreased immunological competence including those receiving immunosuppressive therapy (The immune response to this vaccine may be reduced. Inoculation with this vaccine should be considered with reference to the electronic package inserts of other drugs.)</u></p>

N/A: Not Applicable. No corresponding language is included in the current Precautions.

Pharmaceuticals and Medical Devices Agency

3-3-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013 Japan
 E-mail: safety.info@pmda.go.jp